Purpose: Nonneurogenic chronic urinary retention is an uncommon problem in young female individuals, and a well characterised causes is Fowler syndrome (primary disorder of urethral sphincter relaxation). Intermittent catheterisation is often challenging, and gold standard treatment sacral neuromodulation is not widely available. Urethral sphincter botulinum toxin injection has been shown to be effective cross-sectionally, however little is known about long-term outcomes.Methods: Female individuals presenting with urinary retention due to Fowler syndrome were reviewed retrospectively from a single tertiary referral centre over an 11-year period (2010–2021). One hundred units of onabotulinum toxin A (BoTX-A) was injected into the striated urethral sphincter in a divided dose by the periurethral approach. Efficacy and side effects were assessed 4 weeks after injection.Results: Thirty-three female individuals with a mean age of 40.1±14.1 years received 165 unique urethral sphincter BoTX-A injections over 11 years. Nineteen individuals (57.6%) presented in acute urinary retention, and 28 (84.8%) were reliant on catheterisation. Twenty-one individuals (64%) responded to BoTX-A injections and had a significantly raised baseline maximum urethral closure pressure (MUCP), compared to nonresponders (114.6 cm H2O, P=0.012). Side effects were reported following 19 injections (11.5%) however, were mild and transient. Fifteen individuals received more than 1 botulinum toxin injection (median, 3 injections), with a median interval of 112 days (interquartile range) and efficacy persisted following repeat injections and no safety concerns were seen.Conclusions: Sphincter botulinum toxin through the periurethral approach is safe and effective following repeat injections, and offers a low-cost, minimally invasive alternative to managing female chronic urinary retention due to Fowler syndrome, particularly when there was a high baseline MUCP.
9 February 2026 in Clinical Neurophysiology Practice
Purpose: The existing literature on the sacral dermatomal evoked potentials (dSEPs) is limited. This study aims to develop stimulating parameters and establish normative values for S2, S3, and S4 sacral dermatomes in healthy adult populations. Methods: Twenty healthy adult volunteers were enrolled in the study. The study was ethically approved, and written consent for participation was provided. All participants underwent tibial, pudendal, S2, S3, and S4 dSEPs. Stimulating and recorded parameters were established for all evoked potentials. P40 latency, amplitude, and interpeak parameters were calculated for each waveform. A comparison was made between tibial, pudendal somatosensory evoked potentials, and all sacral dSEPs. Normative values were generated for sacral dSEPs based on various height, age, and Body Mass Index (BMI) parameters. Results: The sacral dSEPs were well tolerated and recorded in all participants. S2 latency was mildly influenced by age and height, while S3 and S4 latencies were unaffected by age or height. BMI does not affect the S2 and S3 latencies but mildly affects the S4 latency. Sacral dSEP latencies were comparable with pudendal SEPS but not with the tibial somatosensory evoked potential. Conclusions: The S2, S3, and S4 sacral dSEPs can be used as diagnostic tools to evaluate sacral nerve lesions such as cauda equina syndrome and Tarlov cysts, complementary to pudendal and tibial somatosensory evoked potentials.